Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study-Reference-Cited by-同舟云学术

Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study

Published:2024-07-23 Issue:4 Volume:5 Page:887-891
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Hulin Cyrille¹^ORCID,Quignot Nadia²^ORCID,Jiang Heng²,Mechiche Hakima³,Désaméricq Gaëlle³

Affiliation:

1. Hematology unit Hospital Center University De Bordeaux Bordeaux France

2. Certara Evidence & Access Paris France

3. Amgen SAS Boulogne‐Billancourt France

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.946

Reference13 articles.

1. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

2. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

4. European Medicines Agency.CHMP summary of positive opinion for Kyprolis.European Medicines Agency;2015. Accessed September 24 2015.https://www.ema.europa.eu/documents/smop‐initial/chmp‐summary‐positive‐opinion‐kyprolis_en.pdf

5. European Medicines Agency.CHMP post‐authorisation summary of positive opinion for Kyprolis.European Medicines Agency;2016. Accessed May 26 2016.https://www.ema.europa.eu/documents/smop/chmp‐post‐authorisation‐summary‐positive‐opinion‐kyprolis_en.pdf